Vect-Horus Enters Exclusive License Agreement with Ionis Pharmaceuticals to Advance Systemic Delivery of RNA-Targeted Medicines for Neurological Diseases

Contributed by: Business Wire

Logo

Tags

Mental Health

Research

Biotechnology

Other Health

Health

Pharmaceutical

Other Science

Science

Oncology

Ionis Pharmaceuticals

More Like This

Vect-Horus Enters Exclusive License Agreement with Novo Nordisk to Develop Targeted Therapeutics

Vect-Horus Strengthens its Scientific Advisory Board with the Appointment of Pr. Xavier Declèves

PR Newswire associated0

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

PR Newswire associated0

Hox Therapeutics and Vernalis announce a drug discovery collaboration in oncology

GlobeNewswire associated0

4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy

Shanghai Argo Announces Multi-Program RNAi Licenses and Strategic Collaborations with Novartis

Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)

Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset